Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity

Natera Inc. (NTRA) announced an update on their ongoing clinical study.

Natera’s new trial, “Circulating Tumor DNA Assessment in Early-Stage Endometrial Cancer (SIGNAL-EMC 101),” aims to show whether its Signatera blood test can safely guide follow-up treatment for women with early-stage, higher-risk endometrial cancer. The key goal is to see if women who test negative on Signatera after surgery can skip standard vaginal radiation and still have similar three-year outcomes, which would support a less intensive care path and broaden the clinical use of Natera’s test.

The main intervention is Natera’s Signatera Genome ultra-sensitive blood test, which looks for tiny traces of tumor DNA in the blood after surgery. The test is meant to pick out patients who have no clear signs of remaining disease so doctors can tailor follow-up treatment more precisely, either by observation alone or by adding standard vaginal brachytherapy.

This is an interventional, randomized study with two parallel groups. One group is observed after surgery using Signatera guidance, while the other group receives standard vaginal brachytherapy. Both patients and investigators are blinded to most follow-up test results to keep the comparison fair. The main goal is treatment-focused: to test whether a Signatera-guided observation strategy can match the effectiveness of standard radiation while reducing treatment burden.

The trial is listed as not yet recruiting, with the study first submitted on December 30, 2025. The most recent update to the record was posted on January 13, 2026, signaling that planning and setup are active ahead of site opening and enrollment. Key future dates, including primary and final completion, are not yet posted, so investors should treat this as an early-stage, multi-year clinical catalyst.

For investors, this update reinforces Natera’s push to expand Signatera beyond colorectal and other solid tumors into gynecologic cancers, widening its total addressable market in minimal residual disease testing. A successful outcome could support stronger payer coverage, deeper oncologist adoption, and higher recurring testing volumes, which would be supportive for NTRA’s valuation. It also raises competitive pressure on other liquid biopsy and MRD players such as Guardant Health and NeoGenomics, who are also seeking clinical proof in new tumor types. While near-term revenue impact will be limited until data readouts, the new trial should be viewed as a positive signal for Natera’s long-term growth story and may bolster bullish sentiment in the precision oncology testing space.

This study is currently in the setup phase with its listing recently updated, and further details are available on the ClinicalTrials portal.

To learn more about NTRA’s potential, visit the Natera Inc. drug pipeline page.